How Wegovy and Ozempic Affect Blood Sugar
Wegovy (semaglutide 2.4 mg weekly) and Ozempic (semaglutide 0.5-2 mg weekly) are both GLP-1 receptor agonists from Novo Nordisk. They lower blood sugar by mimicking GLP-1, which boosts insulin release, slows gastric emptying, and reduces glucagon after meals. Both improve A1C (average blood sugar over 2-3 months) in type 2 diabetes patients, with effects scaling to dose.
Wegovy shows slightly stronger A1C reductions at equivalent doses due to its higher maximum (2.4 mg vs. Ozempic's 2 mg cap), but head-to-head trials are limited since Wegovy targets obesity, not diabetes primarily.[1]
Key Trial Data on A1C Reductions
- Ozempic (SUSTAIN trials): In type 2 diabetes patients, doses of 1 mg weekly reduced A1C by 1.5-1.8% from baseline (8-9%) over 30-56 weeks, vs. 0.8-1.0% for placebo or sitagliptin.[2]
- Wegovy (STEP trials, obesity focus): Among type 2 diabetes subgroups (20-40% of participants), 2.4 mg weekly cut A1C by 1.6-2.0% over 68 weeks, outperforming placebo by 1.2-1.6%. Non-diabetics saw smaller drops (0.4-0.5%).[3]
At 2.4 mg, Wegovy edges Ozempic's max dose for A1C lowering, but differences are small (0.2-0.4%) and not directly compared in identical populations.
Dosing and Real-World Differences
Ozempic starts at 0.25 mg and titrates to 1-2 mg for diabetes control. Wegovy ramps to 2.4 mg over 16 weeks for weight loss, reaching higher steady-state levels faster in practice. Both cause similar fasting blood sugar drops (20-30 mg/dL), but Wegovy's higher dose sustains effects longer in obesity patients with insulin resistance.[1][3]
| Dose | Ozempic A1C Drop | Wegovy A1C Drop |
|------|------------------|-----------------|
| 1 mg | 1.4-1.6% [2] | N/A |
| 2-2.4 mg | 1.6-1.8% [2] | 1.8-2.0% [3] |
Who Sees Bigger Blood Sugar Benefits?
Type 2 diabetics on Ozempic get targeted glycemic control; prediabetics or obese non-diabetics on Wegovy see modest improvements (A1C <1%). Wegovy may outperform in insulin-resistant obesity due to greater weight loss (15% body weight vs. Ozempic's 10-12%), indirectly aiding sugar control.[3][4]
Side Effects Tied to Blood Sugar Effects
Both risk hypoglycemia (<1-5% incidence, mostly with insulin/sulfonylureas), nausea (20-40%), and GI issues that delay carb absorption, enhancing sugar-lowering. No major differences; Wegovy's higher dose slightly raises GI events.[1]
When to Choose One Over the Other for Blood Sugar
Prescribe Ozempic for diabetes-first (FDA-approved); Wegovy for obesity with secondary sugar benefits (not diabetes-approved). Compounded semaglutide versions mimic effects at custom doses.[4]
[1]: Novo Nordisk prescribing info, ozempic.com and wegovy.com
[2]: SUSTAIN-6 trial, NEJM 2016
[3]: STEP 2 trial (diabetes subgroup), NEJM 2021
[4]: ADA Standards of Care 2023, diabetesjournals.org